GHRP-6
PeptideGHRP-6 (Growth Hormone-Releasing Peptide-6) is a synthetic hexapeptide (His-DTrp-Ala-Trp-DPhe-Lys-NH2) that potently stimulates growth hormone secretion. Developed in the 1980s by Cyril Bowers, it was the first synthetic peptide shown to specifically elicit dose-dependent GH release both in vitro and in vivo. GHRP-6 acts through the ghrelin receptor (GHS-R1a) and CD36 receptor, exhibiting not only GH-releasing properties but also significant cytoprotective, cardioprotective, and wound healing effects. It increases IGF-1 levels, stimulates appetite, and has demonstrated tissue-protective properties in multiple preclinical and clinical studies. While primarily researched for GH deficiency, emerging evidence supports its potential in wound healing, scar prevention, and cardioprotection.
Quick Answer
What it is
GHRP-6 (Growth Hormone-Releasing Peptide-6) is a synthetic hexapeptide (His-DTrp-Ala-Trp-DPhe-Lys-NH2) that potently stimulates growth hormone secretion. Developed in the 1980s by Cyril Bowers, it was the first synthetic peptide shown to specifically elicit dose-dependent GH release both in vitro and in vivo.
Key findings
- Grade A: Growth Hormone Release
- Grade B: IGF-1 Levels
- Grade B: Myocardial Protection (Cardiovascular Health)
Safety
No specific caution or interaction language was detected in the current summary/outcome notes.
⚠️ Research Notice
This peptide information is for educational and research purposes only. Peptides may not be FDA-approved for human use and may only be legally available for research purposes. Consult qualified healthcare professionals before considering any peptide compounds.
ℹ️ Quick Facts: GHRP-6
Quick Facts: GHRP-6
- Best Evidence:Grade B
- Conditions Studied:6
- Research Outcomes:13
- Grade A Findings:1
- Grade B Findings:4
- Key Effect:Cardiovascular Health
Detailed Outcomes
Evidence by Condition
Research Citations (33)
Related Peptides
Humanin
Peptide3 shared conditions · 23 outcomes
Humanin (HN) is a 24-amino-acid mitochondrial-derived peptide encoded within the 16S rRNA gene of mitochondrial DNA. Discovered in 2001 from preserved brain tissue of Alzheimer's patients, it demonstrates potent neuroprotective, cytoprotective, and metabolic regulatory effects. Humanin levels decline with age but remain stable in long-lived species and are elevated in offspring of centenarians.
BPC-157
Peptide3 shared conditions · 25 outcomes
BPC-157 is a synthetic 15-amino-acid peptide derived from human gastric juice proteins. B-GRADE for tendon healing (6 studies, 180 participants) and gastric ulcer healing (8 studies, 240 participants). C-GRADE for ligament healing, muscle recovery, wound healing, and neuroprotection. CRITICAL CAVEAT: Nearly all evidence is from ANIMAL studies - human clinical trials are extremely limited. Popular in biohacking/sports communities but regulatory status unclear. NOT FDA-approved. Underground/gray market sourcing raises purity and safety concerns.
TB-500
Peptide2 shared conditions · 23 outcomes
TB-500 is a synthetic fragment of Thymosin Beta-4, a naturally occurring 43-amino acid peptide present in most human cells. It has been investigated for its potential role in tissue repair, wound healing, and regeneration. Research, primarily in animal models, suggests it may promote angiogenesis, cell migration, and reduce inflammation. Human clinical trials are limited.
Sermorelin
Peptide2 shared conditions · 18 outcomes
Sermorelin (GHRH 1-29) is a 29-amino-acid synthetic analog of growth hormone-releasing hormone (GHRH) that retains full biological activity. It was FDA-approved in 1990 for diagnostic use and in 1997 for treating childhood growth hormone deficiency. Sermorelin stimulates natural GH release from the pituitary gland through the hypothalamic-pituitary axis, producing physiological GH patterns with built-in safety through somatostatin feedback regulation.